BioNTech and OncoC4 Announce Strategic Collaboration
Tuesday, March 21, 2023
BioNTech and OncoC4 announced that they have entered into an exclusive worldwide licence and collaboration agreement to develop and commercialise OncoC4’s next-generation anti-CTLA-4 monoclonal antibody candidate, ONC-392, as monotherapy or combination therapy in various cancer indications.
Under the terms of the agreement, OncoC4 will receive a $200 million upfront payment and is eligible to receive development, regulatory and commercial milestone payments as well as double-digit tiered royalties.
- BioNTech will receive exclusive worldwide licence from OncoC4 to develop and commercialise its anti-CTLA-4 monoclonal antibody candidate, ONC-392
- BioNTech and OncoC4 will co-develop ONC-392 as monotherapy or in combination with anti-PD1 in various solid tumour indications, with a randomised Phase 3 trial planned to start in 2023
- BioNTech also plans to combine ONC-392 with proprietary oncology product candidates to evaluate complementary modes of action with the aim to increase therapeutic effect and unlock larger patient populations
Because of its specific mechanism of action, ONC-392 has the potential to broaden the reach of CTLA-4-targeting immunotherapy. This antibody is a valuable addition to the immuno-oncology portfolio, whether used alone or in combination with personalised immunotherapies.
